May 15, 2022
Article
The findings came from a post-hoc analysis of the phase 3 ARCHES trial.
February 19, 2022
Article
Long-term data from the phase 3 JAVELIN Bladder 100 trial continued to show an overall survival (OS) boost with frontline avelumab maintenance in patients with metastatic urothelial cancer.
February 18, 2022
Article
The phase 3 PROpel trial showed that adding the PARP inhibitor olaparib to abiraterone acetate in the frontline setting significantly improved radiographic progression-free survival versus placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer.
September 14, 2021
Article
“Although numbers of participants with certain disease risk features were small, the DFS benefit was consistent across subgroups,” said lead study author Toni K. Choueiri, MD.